Details for Patent: 11,666,573
✉ Email this page to a colleague
Which drugs does patent 11,666,573 protect, and when does it expire?
Patent 11,666,573 protects ERZOFRI and is included in one NDA.
This patent has seven patent family members in six countries.
Drugs Protected by US Patent 11,666,573
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,666,573
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018354431 | ⤷ Sign Up | |||
| Canada | 3077224 | ⤷ Sign Up | |||
| European Patent Office | 3700531 | ⤷ Sign Up | |||
| Japan | 2021501200 | ⤷ Sign Up | |||
| Japan | 7337080 | ⤷ Sign Up | |||
| Russian Federation | 2020113888 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
